A protocol for systematic review and meta-analysis of optimizing treatment for malaria
Renyan Zhang, MD, Xing Dong, MD, Junyao Wang, MD, Ying Guo, MD, Yong Dai, PhD*  

Abstract  
Background: Malaria remains a global health threat for centuries. In recent years, a rising resistance of Plasmodium falciparum to current standard artemisinin-based combination therapies (ACTs) leads to increasing treatment failures and requires for optimized treatment. Here, we intend to make a systematic review and meta-analysis of optimizing treatment for malaria, so as to find a potential optimal treatment.  
Methods: We will search electronic databases: the Cochrane Infectious Diseases Group (CIDG) Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Web of Science from their inception to 1 July, 2020. We will also search International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov, and contact with authors when necessary. Two authors will independently collect and select data, and the statistical analyses will be conducted by Revman V.5.3 software.  
Results: We will evaluate efficacy and safety of modified ACTs for uncomplicate malaria, comparing with standard ACTs in all eligible clinical studies.  
Conclusion: In this study, we will offer clinical evidence for optimizing treatment for malaria.  
Registration number: INPLASY202070115  
Abbreviations: ACTs = artemisinin combination therapies, CENTRAL = the Cochrane central register of controlled trials, CHSRI = the Cochrane Handbook for, CIDG = the Cochrane infectious diseases group, GRADE = the grading of recommendations, assessment, development and evaluation, ICTRP = International Clinical Trials Registry Platform, INPLASY = International platform of registered systematic review and meta-analysis protocols, PICO = participants, interventions, comparators, and outcomes, PRISMA-P = the preferred reporting items for systematic review and meta-analysis protocols, RCT = randomized controlled trials, WHO = World Health Organization.  
Keywords: artemisinin combination therapies, malaria, meta-analysis, protocol, systematic review  

1. Introduction  
Malaria is a mosquito-borne parasitic disease, causing 400 thousand deaths or so globally every year, with most dead cases in Africa and South Asia.[1] There are 6 species of plasmodium can cause human malaria, namely Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale curtisi, Plasmodium ovale wallikeri and Plasmodium knowlesi,[2] among which P falciparum claims for the majority of morbidity and mortality, and is much prone to develop resistance to current antimalarial agents. The malaria infection can result in a spectrum of clinical symptoms, characterized by fever, chills, anemia, headache, nausea, muscle pain and severe malaria (including cerebral malaria, severe anemia, acute respiratory stress, multiple organ failure) and even death.[3,4] After the discovery and utility of quinine extracted from bark of the cinchona tree, the morbidity and fatality number had sharply declined, which lost efficacy not long after using owing to resistance, unfortunately. The malaria cases of morbidity and fatality had gone through a boost for a long period until a Chinese scientist Yoyo Tu extracted artemisinin from leaves of Artemisia Annua Linn., which was inspired by Zhou Hou Bei Ji Fang, one of ancient Chinese Medicine Classics, that serves as a handbook of prescriptions for emergencies.[5]  
In light of the occurrence of resistance to quinine, World Health Organization (WHO) has recommended artemisinin-based combination therapies (ACTs) as standard treatment for uncomplicated malaria since 2005.[6] Nevertheless, an increasing number of treatment failures due to resistance found in Southeast Asia, manifesting as delayed parasite clearance time, worries people of global malaria control and elimination.[7–10] Researchers have been working on developing effective vaccines for malaria which has been well reviewed.[11] There are several
vaccines are undergoing clinical trial phases, among which RTS,S was reported to be successful in preventing nearly 30% onset of severe malaria, and is now under phase 3 clinical trial. Without available vaccine and novel antimalarial drugs yet, ACTs are still top choice among all therapies for now, though there are thousands of candidate chemicals and hundreds of compounds showing promising antimalarial effects in preclinical stage and clinical trials. To make the maximum use of ACTs, proper alterations in standard ACTs could be benefit for containing malaria cases all over the world. In this study, we will evaluate the safety and efficacy of other interventions in ACTs of included studies, so as to provide evidence for modifications of standard ACTs to sustain the progress we have made in malaria control over the years.

2. Methods

2.1. Study registration

This meta-analysis was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 26 July, 2020 (registration number INPLASY202070115). The Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement and the Cochrane Handbook for Systematic Reviews of Interventions (CHSRI) will be carefully followed throughout the process.

2.2. The inclusion criteria

2.2.1. Types of studies. Studies that report randomized controlled trials (RCTs) and quasi-RCTs of comparison between standard ACTs and other administrations for uncomplicated malaria are considered for inclusion in this study. Studies involving non-RCTs, animal experiments, case reports, reviews will be excluded.

2.2.2. Types of participants. Children over 5 years of age and unpregnant adults who are diagnosed with uncomplicated malaria regardless of malaria species are eligible for our study. Patients treated with antimalarial agents within 48 hours before enrollment or allergic to any drug of ACT will be excluded. The nationality, race, educational or financial status, and occupation are not limited. Patients diagnosed with severe malaria will not be included.

2.2.3. Types of interventions. The interventions of the experimental group in this study include ACTs with either additional antimalarial agents or modified combination of the standard ACTs in both types of medicine, dosage and course.

2.2.4. Types of outcomes. The main outcomes are parasitemia in patient’s peripheral blood smears and parasite clearance time. The secondary outcomes are body temperature (°C), weight (kg), hemoglobin (g/dl), red blood cell (RBC) count (×10¹²/l), white blood cell (WBC) count (×10⁹/l), platelet count (×10¹²/l), Alanine aminotransferase (ALT) (U/l) and Aspartate aminotransferase (AST) (U/l).

2.3. Collection and analysis of data

2.3.1. Search strategy. Author Wang will carry out a thorough search in electronic databases: the Cochrane Infectious Diseases Group (CIDG) Specialized Register, the Cochrane Central Register of Controlled Trials (CEN-TRAL), PubMed, Embase, Web of Science from their inception to 1 July, 2020. We will also search the International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov, using medical subject headings from Mesh plus free words to get complete searching results. We will contact with authors when necessary. The detailed information of electronic search is listed in Table 1.

2.3.2. Selection and extraction of data. All of the authors will be trained with PRISMA-P and CHSRI from the beginning. Zhang and Wang will independently select data and check the title, abstract, and content of all enrolled studies for their eligibility. All repetitions and studies not met the inclusion criteria will be excluded. Then, they will cross-check their included and excluded studies. Study with uncertainty will be presented to the third author or the panel to judge if they are eligible for this study.

2.3.3. Assessment of risk of bias and quality of evidence. The two authors will independently evaluate the methodology quality with the Cochrane’s risk of bias tool, Review Manager 5.3 (Revman V.5.3), basing on the CHSRI. All uncertain studies will be presented to the panel or consult with experts. The quality of evidence will be assessed in the guidance of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method. The following aspects will be involved: random sequencing generation, allocation concealment, blinding of outcomes, completeness of outcomes and measures, reporting bias and other sources of biases, for instance, conflicts of interest etc.

2.4. Statistical analysis

2.4.1. Synthesis of data. Basing on the principle of participants, interventions, comparators, and outcomes (PICO), we will draw a basic feature table of all included studies that indicates all the general information and differences in methodology, and help us determine whether the clinical data can be quantitatively synthesized.

2.4.2. Measures of effect size. Author Dong will perform the statistical analyses with Revman V.5.3 software. The dichotomous data will be processed with risk ratio (RR) and a 95%
confidence interval (CI) will be calculated. The weighted mean difference (WMD) or standard mean difference (SMD) with a 95% CI will be calculated as for continuous outcomes.

2.4.3. Assessment of heterogeneity. The heterogeneity of included data will be assessed by the Cochrane’s Q test and be quantified with I² test. We will adopt a fixed effect model with I² > 50%, while a random effect model with I² ≤ 50% will be declined.

2.4.4. Sensitivity analysis. We will evaluate the stability of all included results by excluding the homogeneity. When studies are of low quality, we will perform a sensitivity analysis with Revman V.5.3.

2.4.5. Assessment of reporting bias. Reporting bias will be evaluated when more than 10 studies are included by making funnel plots.

2.4.6. Subgroup analysis. When necessary, we will conduct a subgroup analysis of the included studies with high heterogeneity, in order to find out source of heterogeneity, which may also lead us to a certain population that are more sensitive to the regimen.

3. Discussion
Malaria is still a leading killer of hundreds of thousands of lives globally, of which children under 5 years of age and pregnant women account for the majority. With the discovery and development of quinine and artemisinin, we have achieved great progress in malaria control. In order to delay the occurrence of resistance to artemisinin drugs, WHO has recommended ACTs as the standard treatment of uncomplicated malaria since early 2000s. However, a long-term abuse of nonstandard monotherapy in treating malaria in certain areas has induced multiple plasmodium, especially of falciparum species, to develop resistance to almost any of current frontline antimalarial agents, which will vastly challenge the progress we have made over the years. People now are concerned that the increasing number of treatment failures in South Asia may quickly spread globally, especially Africa where burned the majority of mortality all over the world. Though there are many vaccines undergoing clinical trials for years, no vaccine has been proven to be highly safe and effective so far. Without effective vaccine, we can only depend on medication to treat malaria. In this study, we will review all related clinical reports of new modification on the standard ACTs and analyze the clinical data to evaluate the safety and effectiveness of these therapies and to provide solid evidence for potential alternative ACT treatment in future utility. We will try to thoroughly search the electronic databases, clinical online registration websites and get in touch with authors of included studies for more detailed information to get a complete data as possible. But we have to admit that there could be limitations for possible lack of related unpublished documents, and the scale or quality of RCTs that we include may affect our analyses. We hope
that more multiple-center RCTs of large scale and of high quality could be reported to offer more solid evidence in the future.

**Author contributions**

**Conceptualization:** Renyan Zhang  
**Data collection:** Junyao Wang, Renyan Zhang  
**Software:** Xing Dong  
**Statistical analysis:** Xing Dong  
**Supervision:** Ying Guo  
**Writing – original draft:** Renyan Zhang  
**Writing – review & editing:** Yong Dai

**References**

[1] World Malaria Report 2019. World Health Organization. https://www.who.int/malaria/publications/world-malaria-report-2019/en/. Published 2019. Accessed July 29, 2020.

[2] Ahmed MA, Cox-Singh J. Plasmodium knowlesi - an emerging pathogen. ISBT Sci Ser 2015;10(Suppl 1):134–40.

[3] Cunnington AJ, Walther M, Riley EM. Piecing together the puzzle of severe malaria. Sci Transl Med 2013;5:211s218.

[4] Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995;332:1399–404.

[5] Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011;17:1217–20.

[6] Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007;4:253–30.

[7] Aney F, Wrikowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50–5.

[8] Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014;371:411–23.

[9] Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455–67.

[10] Noedl H, Se Y, Schrecker K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008;359:2619–20.

[11] Schwartz L, Brown GV, Genton B, et al. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012;11:11.

[12] Douglass AD, Baldeviano GC, Lucas CM, et al. A Pirh5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe 2015;17:130–9.

[13] Greenwood B, Doumbo OK. Implementation of the malaria candidate vaccine RTS,S/AS01. Lancet 2016;387:318–9.

[14] Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013;341:1339–65.

[15] Spring M, Murphy J, Nielsen R, et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013;31:4975–83.

[16] Theisen M, Roeßen W, Singh SK, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 2014;32:2623–30.

[17] Moorhys VS, Okwo-Bele JM. Final results from a pivotal phase 3 malaria vaccine trial. Lancet 2015;386:5–7.

[18] Gamo FJ, Sanz LM, Vidal J, et al. Thousands of chemical starting points for antimalarial lead identification. Nature 2010;465:305–10.

[19] Spangenberg T, Burrows JN, Kowalczyk P, et al. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One 2013;8:e62906.

[20] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[21] Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10:Ed000142.

[22] Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med 2017;23:917–28.